Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy.
- Author:
Jian-hua FU
1
;
Tie-hua RONG
;
Xiao-dong LI
;
Hui YU
;
Guo-wei MA
;
Hua-qing MIN
Author Information
- Publication Type:Clinical Trial
- MeSH: Combined Modality Therapy; Esophageal Neoplasms; mortality; therapy; Female; Humans; Male; Stents
- From: Chinese Journal of Oncology 2004;26(2):109-111
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the benefits of post-stenting radiotherapy and/or chemotherapy for unresectable esophageal carcinoma.
METHODSFifty-three patients with unresectable esophageal carcinoma were randomly divided into two groups: patients in group A (n = 27) were treated with stenting alone, and those in group B (n = 26) were treated with stenting followed by radiotherapy and/or chemotherapy. Comparison was made by assessing their survival time, quality of life (QOL), degree of dysphagia, and stenting-related morbidity, respectively.
RESULTSThere was no statistically significant improvement in dysphagia and QOL between the two groups. Although there was no difference in the frequency of stenting-related complications, re-stenosis occurred much less frequently in group B patients (P = 0.007). The mean survival time of patients was 245 +/- 41 days and 262 +/- 43 days in group A and group B, respectively. There was no significant difference between the two groups (P = 0.813).
CONCLUSIONBesides decreased recurrence of stenosis, post-stenting radiotherapy and/or chemotherapy does not provide additional benefits for survival.
